Cancer du sein luminal et apport des classifications intrinsèques moléculaires : comment identifier les tumeurs luminales A et B en 2015 ?

Glyoxalase 1 and protein kinase Cλ as potential therapeutic targets for late‑stage breast cancer

“…Given that luminal B type breast cancer exhibits expression of ER and/or PgR, the correlation between GLO 1 and PKCλ in luminal B tumors may be related to the ER and/or PgR positivity of those tumors. The luminal B subtype is associated with poorer clinical outcomes compared with the luminal A subtype (76). These results therefore suggest that high expression of GLO 1 and PKCλ may be contributed to cancer progression in luminal B.…”

Integrative single‐cell sequencing analysis distinguishes survival‐associated cells from the breast cancer microenvironment

“…Of note, previous studies showed that the ER+ subtype has the best prognosis, but the worse prognosis for HER2+ and TNBC subtypes. 2,3 Interestingly, we found that Scissor+ tumor cells were mainly concentrated in breast cancer patients with HER2+ and TNBC subtypes rather than the ER+ subtype (Figure 2C), revealing that the epithelial cell heterogeneity has a significant impact on patient survival. Besides, we further divided epithelial cells into three common subpopulations: basal cells (KRT14+, KRT5+), luminal 1 cells (SPLI+, PROM1+), and luminal 2 cells (ANKRD30A+, SYTL2+) (Figure S3), 23 and found that Scissor+ tumor cells could be distributed in all three subpopulations, particularly the highest proportion of luminal 1 cells and the lowest proportion of basal cells (Figure 2C).…”

“…Breast cancer is the most common malignant tumor and the main cause of cancer death in women 1 . Clinically, breast cancer patients are widely divided into ER + (Luminal A/Luminal B), HER2 + and triple negative breast cancer (TNBC) subtypes through estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) 2,3 . Different breast cancer subtypes correspond to different treatment methods and prognosis 4,5 .…”

Immunohistochemical Overexpression of Cyclin D1 in Tunisian Invasive Breast Carcinoma Women

“…14 We identified five molecular subtypes: Luminal A (LA) if ER and/or PR positive, HER2 negative and Ki-67 < 20%; Luminal B like (LB-Like) if ER and/or PR positive, HER2 negative and Ki-67 > 20%; Luminal B (LB) if ER and/or PR positive and HER2 positive; HER2-positive breast cancer (HER2 +) if both ER and PR negative and HER2 positive and finally, Triple Negative Breast Cancer (TNBC) if HR and HER2 negative. 17 The pathological TNM classification and staging was done as per American Joint Committee on Cancer (AJCC) guidelines. 18 Clinical data were collected from medical records at the department of Oncology of the Habib Bourguiba University Hospital (Sfax, Tunisia) and they included age, menopausal status, distant metastasis at diagnosis and outcomes.…”